Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- PMDA Reviewing Safety Risks for Imfinzi and Bavencio
June 27, 2022
- Health Minister Visits Takeda Manufacturing Site for Novavax Jab, Stresses Need to Handle Diverse Modalities in Japan
June 24, 2022
- Japan Logs 496 Pharma Product Recalls in FY2021; Self-Inspections, COVID Drive Surge
June 24, 2022
- Industry Groups Seek Financial Aid for Securing Pandemic Response Supplies
June 23, 2022
- Pharma-Backed Upper House Candidates Kick Off Campaigning for July 10 Poll
June 23, 2022
- Japan Shelves Decision on Shionogi’s COVID Pill with Experts at Odds, Another Session Likely Next Month
June 23, 2022
- Takashi Yasukawa Named Pharmaceutical Management Director
June 22, 2022
- Govt Panel Agrees to Add Xofluza to Flu Drug Stockpile
June 22, 2022
- Kazuhiro Oshima Tapped as Vice Health Minister, Katsufumi Jo as First Councilor for Pharma Industry Promotion
June 22, 2022
- Pemigatinib, Azacitidine, TAK-611 Get Orphan Tag in Japan
June 22, 2022
- Health Minister Defends Govt Purchase Pact for Shionogi’s COVID Pill
June 21, 2022
- Japan Approves Janssen’s COVID Jab, Sanofi’s Sutimlimab, Olumiant’s Alopecia Use and More
June 21, 2022
- MHLW Wants to Boost Preparedness with Proposed Pandemic Response Division: Minister
June 20, 2022
- PMDA Clears All Its Review Targets, Processed Relief Claims at Record Speed in FY2021
June 20, 2022
- Govt Officially OKs Launch of Pandemic Response Agency, Japan CDC
June 20, 2022
- Japan Detects 11 More Probable Cases of Mysterious Hepatitis in Children
June 20, 2022
- As Election Campaigns Begin, Parties Pitch Policies to Bolster Drug Development, Supply Chains
June 17, 2022
- New NIBIOHN Chief Eager to Bridge Void to Develop Innovative Drug Discovery Platform
June 17, 2022
- First Two Vaccine Projects Adopted for SCARDA Funding
June 17, 2022
- Feburic, Samsca, and More Face First Generics in June Listing, No Xarelto/Eylea AGs
June 16, 2022
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…